Michael T. Lin, M.D.July 15, 2022

FDA 483 - Michael T. Lin, M.D. - July 15, 2022

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Michael T. Lin, M.D.

Record Details

An FDA inspection of Michael T. Lin, M.D., a clinical investigator in New York, NY, revealed a significant violation related to human subject protection. The firm failed to obtain informed consent from a human subject prior to administering a study drug and conducting related tests, as required by protocol and federal regulations. This indicates a serious lapse in ethical and regulatory compliance for clinical trials.

Company: Michael T. Lin, M.D.
Inspection Date: July 15, 2022
Product Type: Drugs
Office: Division of Human and Animal Food Operations - East I
Person: Omadevi Somai

Open in Dashboard

ID · cf90a592-55c4-4905-8cfb-d91d453cb135